TY  - JOUR
AU  - Ray, Kausik K
AU  - Leiter, Lawrence A
AU  - Müller-Wieland, Dirk
AU  - Cariou, Bertrand
AU  - Colhoun, Helen M
AU  - Henry, Robert R
AU  - Tinahones, Francisco J
AU  - Bujas-Bobanovic, Maja
AU  - Domenger, Catherine
AU  - Letierce, Alexia
AU  - Samuel, Rita
AU  - Del Prato, Stefano
PY  - 2018
DO  - 10.1111/dom.13257
UR  - http://hdl.handle.net/10668/12122
T2  - Diabetes, obesity & metabolism
AB  - To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY...
LA  - en
KW  - PCSK9
KW  - mixed dyslipidaemia
KW  - non-HDL cholesterol
KW  - type 2 diabetes
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Anticholesteremic Agents
KW  - Blood Glucose
KW  - Cholesterol, HDL
KW  - Diabetes Mellitus, Type 2
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Dyslipidemias
KW  - Female
KW  - Glycated Hemoglobin
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Hypoglycemic Agents
KW  - Lipid Metabolism
KW  - Male
KW  - Middle Aged
KW  - Proprotein Convertase 9
KW  - Treatment Outcome
TI  - Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
TY  - research article
VL  - 20
ER  -